Entity family

Browse drugs

Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.

3articles mentioning drugs

59drug mentions

1distinct drugs extracted

0%of mentions human-reviewed

Active filtersEntity: mFOLFIRINOX ×

mFOLFIRINOX

This drug is selected. Its supporting articles are shown below.

mFOLFIRINOX3

Articles mentioning mFOLFIRINOX

3 articles · page 1 of 1

Real-world effectiveness of NALIRIFOX versus modified FOLFIRINOX or gemcitabine and nab-paclitaxel in first-line advanced pancreatic adenocarcinoma: a multicentre propensity-matched study

bmjonc · full text · 2026-07-03 · 43 matching annotations

95.9%

Gem/NabP NALIRIFOX

…systemic palliative chemotherapy with NALIRIFOX, mFOLFIRINOX or Gem/NabP between January 2021 and July 2024. Key eligibility criteria re…

Real-world effectiveness of NALIRIFOX versus modified FOLFIRINOX or gemcitabine and nab-paclitaxel in first-line advanced pancreatic adenocarcinoma: a multicentre propensity-matched study

bmjonc · abstract · 2026-07-03 · 9 matching annotations

90.3%

NALIRIFOX gemcitabine oxaliplatin nab-paclitaxel fluorouracil mFOLFIRINOX leucovorin

… for Gem/NabP. Recorded grade ≥3 toxicities appeared lower with NALIRIFOX, although cross-regimen safety comparisons were limited by retr…

530 CD40 agonist mitazalimab + mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma: dose characterization based on exposure response and biomarker analysis from the OPTIMIZE-1 study

jitc · abstract · 2025-11-04 · 7 matching annotations

95.5%

Mitazalimab mFOLFIRINOX

…and 89.5% OS) compared with 450 µg/kg (38.7% PFS and 69.4% OS). Mitazalimab in combination with mFOLFIRINOX demonstrated a manageable safet…